Regeneron Pharmaceuticals is a major pharmaceutical company that develops and sells drugs covering areas of immunology, oncology, ophthalmology, and rare diseases. During the COVID-19 outbreak it developed a widely used monoclonal antibody treatment. Other flagship products include Eylea, an injection to treat age-related macular degeneration and other eye conditions; Dupixent, a therapy for inflammatory diseases like atopic dermatitis, asthma, and chronic rhinosinusitis; and Libtayo, for certain types of cancer. The company was incorporated in 1988.
Regeneron Pharmaceuticals
Regeneron Pharmaceuticals in Fortune Rankings
- Company Information
- Best Companies
- Perks
- Hiring/staffing (past 12 Months)
- Fastest-growing Companies
- Change The World
- Future 50
- Best Large Workplaces In New York
- America's Most Innovative Companies
- Key Financials (last Fiscal Year)
- Profit Ratios
- Earnings Per Share (last Fiscal Year)
- Total Return
- Updated:6/3/26
- Country/Territory:U.S.
- Headquarters:Tarrytown, N.Y.
- Industry:Pharmaceuticals
- CEO:Leonard S. Schleifer
- Website:https://www.regeneron.com
- Ticker:REGN
- Company type:Public
- Revenues ($M):$14,343
- Profits ($M):$4,505
- Market value ($M):$81,683
- Number of employees:15,410
Market value as of March 31, 2026.
- Rank last year:67
- Years on list:7
- U.S. employees:9,100
- U.S. job openings:600
- Year founded:1988
Employees and job openings are U.S.-only.
- 100% health coverage:No
- Unlimited sick days:No
- Telecommuting:Yes
- Job sharing:No
- Subsidized childcare:Confidential
- Compressed work weeks:Confidential
- Fully-paid sabbaticals:No
- On-site fitness/subsidized gym:Yes
- On-site medical care facility:No
- Non-discrimination policy includes sexual orientation:Yes
- Sick days for part-timers:Yes
- College tuition reimbursement:Yes
- Student loan debt repayment:Yes
- # of job applicants:52,430
- Avg. # of applicants per opening:33
- # New graduates hired:419
- Revenue 3 Yr Growth Rank:18
- Revenue 3 Yr Annual Growth Rate:49%
- EPS 3 Yr Growth Rank:55
- EPS 3 Yr Annual Growth Rate:59%
- Total Return 3 Yr Rank:55
- Total Return 3 Yr Annual Rate:24%
- Beat S&P 500 3 Yr Return:no
- Current Streak:1
- Years on List:4
- Sector:Health Care
- Impact Segment:Public Health/Nutrition
- Sector:Health Care
- Overall Score:2.5
- Sector:Health Care
- Industry:Pharmaceuticals
- CEO:Leonard S. Schleifer
- Website:https://www.regeneron.com
- Employees:5,400
- HQ Location:Tarrytown, N.Y.
- Revenues ($M) (Past 12 Months):$5,236
- Profits ($M) (Past 12 Months):$1,155
- Market Value as of Oct. 9, 2019 ($M):$50,054
- Industry:Biotechnology & Pharmaceuticals
- Industry Vertical:Biotechnology
- Founded:1988
- City:Tarrytown, N.Y.
- Sites:5
- Web Address:https://www.regeneron.com
- U.S. Employees:8,076
- U.S. Revenue:-
- Total Worldwide [including U.S.] Revenue in the Latest Fiscal Year:-
- Date info provided (companies may opt to keep some data confidential):July 31, 2021
- Sector:Health Care
- Strongest Dimension:Process innovation
- Years on list:1
- Previous rank:-
- State:New York
- $ millions% change
- Revenues ($M):$14,342.91%
- Profits ($M):$4,504.92.1%
- Assets ($M):$40,558.7-
- Total Stockholder Equity ($M):$31,256.9-
- Profit as % of Revenues:31.4%
- Profits as % of Assets:11.1%
- Profits as % of Stockholder Equity:14.4%
- Earnings Per Share ($):41.50
- EPS % Change (from prior fiscal year):8.2%
- EPS % Change (5 year annual rate):6.3%
- EPS % Change (10 year annual rate):22.4%
- Total Return to Investors (last year):9%
- Total Return to Investors (5 year, annualized):10%
- Total Return to Investors (10 year, annualized):3.6%
Regeneron Pharmaceuticals stock chart
Regeneron Pharmaceuticals in Fortune Rankings
- Fortune 500
- America's Most Innovative Companies
- Fortune Sector Leaders: Health Care
- Best Large Workplaces in New York
- Best Large Workplaces in Biotechnology and Pharmaceuticals
- 100 Fastest-Growing Companies
- Fortune 100 Best Companies to Work For
- Change the World
- 100 Best Large Workplaces for Millennials
- The Future 50